Avenue Therapeutics Receives Positive Listing Determination
MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company ...
Read moreMIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company ...
Read moreReliaable Developers, a leading force in Bangalore's plotted development sector, unveils a striking new logo as a cornerstone of ...
Read more– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested; ...
Read more- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose ...
Read moreBexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; ...
Read more51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) ...
Read moreFrankfurt am Main/ New Delhi, 1 February 2024. Due to the great demand, the organisers are opening up additional halls ...
Read moreFrankfurt am Main/ New Delhi, 1 February 2024. Due to the great demand, the organisers are opening up additional halls ...
Read more30 January 2024 - A group of International Olympic Committee (IOC) Young Leaders are on-site at the Winter Youth Olympic Games ...
Read more– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.